Glucagon-like-peptide-1 agonists and breast cancer outcomes: Emerging advancements in metabolic oncology
NCODA Oncology and Hematology Meeting Abstracts · 13.10.2026 · 2 (2)
DOI: 10.67209/onwi7063 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 13.10.2026. Verfasst von Ariel Hughes und 1 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Discussion
Breast cancer remains the most diagnosed cancer among women, and obesity and metabolic syndrome are associated with increased breast cancer risk, recurrence, and mortality. Prognosis is stage dependent, with nearly 100% 5-year survival for localized disease compared with 33.8% for metastatic disease. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), used to treat obesity and type 2 diabetes, may improve outcomes through anti-inflammatory and immunomodulatory effects.
Objectives
Explain how GLP-1 receptor agonist-mediated metabolic pathways, including inflammation reduction and adipose-related estrogen modulation, may influence breast cancer incidence, recurrence-free survival, and overall survival.
Purpose
To analyze whether the use of GLP-1 RAs is associated with improved patient outcomes, namely the incidence, recurrence-free survival, progression, and overall survival of breast cancer patients.
Methods
A literature review was carried out wherein evidence was extracted from a variety of sources including a retrospective analysis reported at American Society of Clinical Oncology (ASCO) 2026 and a cohort study reported in the Journal of the American Medical Association (JAMA) Network Open in 2026. Data were synthesized to evaluate associations between use of GLP-1 RAs and breast cancer incidence, recurrence-free survival, overall survival, and proposed metabolic mechanisms involving obesity, inflammation, and estrogen production.
Results
Evidence suggests that GLP-1 RAs may influence breast cancer outcomes through both metabolic and potential antitumor effects. In a 2026 study, researchers observed a ~30% decrease in the incidence of breast cancer, which authors noted was comparable to early tamoxifen studies for breast cancer prevention. Across the included studies, use of GLP-1 RAs was consistently associated with improved breast cancer outcomes. The most reported adverse effects were gastrointestinal, including nausea, vomiting, diarrhea, and constipation. In patients with breast cancer and obesity or type 2 diabetes mellitus (T2DM), GLP-1 therapy was associated with reduced all-cause mortality (hazard ratio [HR] 0.09–0.35) and improved recurrence-free survival (HR 0.33–0.44) compared with nonuse or treatment with insulin/metformin. Additionally, GLP-1 exposure was associated with a significantly lower incidence of breast cancer among overweight and obese women undergoing screening (odds ratio [OR] 0.695; 95% confidence intervall [CI] 0.590–0.819; p
Zitieren
APA
Hughes, A., & Ryan, N. (2026). Glucagon-like-peptide-1 agonists and breast cancer outcomes: Emerging advancements in metabolic oncology. NCODA Oncology and Hematology Meeting Abstracts, 2(2). https://doi.org/10.67209/onwi7063
Vancouver
Hughes A, Ryan N. Glucagon-like-peptide-1 agonists and breast cancer outcomes: Emerging advancements in metabolic oncology. NCODA Oncology and Hematology Meeting Abstracts. 2026;2(2). doi:10.67209/onwi7063
BibTeX
@article{Hughes2026,
author = {Hughes, Ariel and Ryan, Neil},
title = {Glucagon-like-peptide-1 agonists and breast cancer outcomes: Emerging advancements in metabolic oncology},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
volume = {2},
number = {2},
doi = {10.67209/onwi7063}
}
EUVIMED